TRDA (Entrada Therapeutics) Interest Coverage: N/A (As of Mar. 2026)


TRDA Entrada Therapeutics Inc TRDA
23 GF Score
Price $7.37
GF Value $0.92
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Entrada Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Entrada Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-42.30 Mil. Entrada Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Entrada Therapeutics's Interest Coverage or its related term are showing as below:


TRDA's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Entrada Therapeutics  (NAS:TRDA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Entrada Therapeutics Interest Coverage Related Terms

Entrada Therapeutics Interest Coverage Historical Data

* Premium members only.

The historical data trend for Entrada Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Entrada Therapeutics Interest Coverage Chart

Entrada Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial 0.00 N/A N/A N/A N/A

Entrada Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

TRDA vs SABS, ACIU, AVXL: Interest Coverage Comparison

For the Biotechnology subindustry, Entrada Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entrada Therapeutics Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's Interest Coverage falls into.


TRDA
23GF Score
Entrada Therapeutics Inc TRDA
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entrada Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Entrada Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Entrada Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-157.90 Mil. And its Long-Term Debt & Capital Lease Obligation was $46.79 Mil.

GuruFocus does not calculate Entrada Therapeutics's interest coverage with the available data.

Entrada Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Entrada Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-42.30 Mil. And its Long-Term Debt & Capital Lease Obligation was $45.47 Mil.

GuruFocus does not calculate Entrada Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Is Entrada Therapeutics (TRDA) Overvalued in 2026?

Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued. The current stock price of $7.37 is trading 701.1% above its estimated GF Value™ of $0.92. GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.

Key valuation signals for TRDA:

  • Interest Coverage: N/A
  • GF Value™: $0.92 vs. price of $7.37 (701.1% above fair value)
  • GF Score™: 23/100 with 4 warning signs

No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entrada Therapeutics Business Description

Address One Design Center Place, Suite 17-500, Boston, MA, USA, 02210
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
23GF Score

Get the complete analysis for TRDA

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.37
Price
$0.92
GF Value